Kezar Life Sciences reports 2023 net loss of $101.9M; cash at $201.4M; trial timelines reiterated

Kezar Life Sciences, Inc.

Cash, cash equivalents and marketable securities totaled $201.4M as of Dec 31, 2023, down from $276.6M year-end 2022.
Net loss for 2023 was $101.9M ($1.40 per share) vs $68.2M ($1.01 per share) in 2022.
R&D expenses for 2023 increased 68% to $85.7M, driven by PALIZADE, PORTOLA trials and milestone payment to Onyx.
Restructuring and impairment charges of $6.2M in Q4 2023 from employee termination benefits and asset impairment.
PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) enrolling; topline data expected mid-2026 and mid-2025 respectively.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kezar Life Sciences, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $7.0 million.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $7.0 million
Result: reported results

Exact text from the filing

Revenue for the year of 2023 was $7.0 million resulting from the upfront payment under the collaboration and license agreement with Everest Medicines.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.